Squadron Capital Llc Sells 4,000 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Squadron Capital Llc sold 4,000 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $25.75, for a total value of $103,000.00. Following the completion of the transaction, the insider directly owned 6,897,764 shares of the company’s stock, valued at $177,617,423. This represents a 0.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Wednesday, August 26th, Squadron Capital Llc sold 18,000 shares of OrthoPediatrics stock. The shares were sold at an average price of $24.28, for a total value of $437,040.00.
• On Tuesday, August 25th, Squadron Capital Llc sold 16,300 shares of OrthoPediatrics stock. The shares were sold at an average price of $24.74, for a total value of $403,262.00.

OrthoPediatrics Price Performance

Shares of KIDS stock opened at $23.32 on Friday. The stock has a market cap of $608.89 million, a price-to-earnings ratio of -13.88 and a beta of 0.98. The business’s fifty day moving average is $21.32 and its 200 day moving average is $18.62. OrthoPediatrics Corp. has a twelve month low of $14.42 and a twelve month high of $26.74. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Research analysts expect that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on KIDS. BTIG Research lifted their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Needham & Company LLC raised their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, OrthoPediatrics presently has an average rating of “Moderate Buy” and an average price target of $26.44.

OrthoPediatrics News Roundup

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during its limited release. The system expands the company’s pediatric trauma and deformity portfolio and could create a long-term revenue and market-share opportunity, though management did not provide specific financial guidance. 3P Pediatric Plating Platform Hip System launch
• Positive Sentiment: Analyst sentiment remains favorable. Piper Sandler raised its target to $25, Needham lifted its target to $35, and BTIG increased its target to $29, while maintaining positive ratings. MarketBeat data shows a “Moderate Buy” consensus with an average target of $26.44.
• Positive Sentiment: Recent quarterly results exceeded expectations: OrthoPediatrics reported a loss of $0.26 per share versus the estimated loss of $0.30, while revenue of $70.51 million surpassed the $68.21 million consensus estimate. BlackRock and other institutional investors also recently initiated or expanded positions.
• Neutral Sentiment: Reported short interest was listed at zero shares, but an invalid change figure makes the data unreliable and limits its usefulness for assessing short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholders associated with Squadron Capital and Jennifer N. Pritzker sold a combined 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The sales reduced their position by roughly 0.56%, leaving ownership of about 6.86 million shares. While modest relative to their remaining stake, repeated insider selling may weigh on investor sentiment, particularly with the stock near its 52-week high. SEC insider transaction filing

Institutional Investors Weigh In On OrthoPediatrics

A number of institutional investors have recently modified their holdings of KIDS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after purchasing an additional 645 shares during the last quarter. Millennium Management LLC boosted its stake in OrthoPediatrics by 55.3% in the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock worth $16,172,000 after purchasing an additional 233,873 shares in the last quarter. Goldman Sachs Group Inc. grew its position in OrthoPediatrics by 112.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after purchasing an additional 106,041 shares during the last quarter. Jane Street Group LLC purchased a new stake in OrthoPediatrics during the 1st quarter valued at about $389,000. Finally, American Century Companies Inc. increased its stake in OrthoPediatrics by 12.5% during the 2nd quarter. American Century Companies Inc. now owns 34,486 shares of the company’s stock valued at $741,000 after purchasing an additional 3,828 shares in the last quarter. 69.05% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.